The Food and Drug Administration approved Vectibix (panitumumab) for patients with colorectal cancer that has spread to other parts of the body following chemotherapy.
Vectibix is a monoclonal antibody that binds to a protein called epidermal growth factor receptor or EGFR on some cancer cells.
The FDA said in a statement that the drug received an accelerated approval after showing effectiveness in slowing tumor growth and, in some cases, reducing the size of the tumor
